ClinicalTrials.gg
CompletedNCT03237481Updated Mar 2, 2026Results posted

Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)

A Phase 3 interventional study of HTX-011 and Bupivacaine HCl in Postoperative Pain, sponsored by Heron Therapeutics. Completed at 24 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Heron Therapeutics · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
418
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
4th of 364
418 · median 70
Started
2017
with 30 others
Phase 3
42 of 364
2 open now
Registered
121st of 364
by date
Lead sponsor
17 of 364
Heron Therapeutics

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 4th largest by enrollment, is one of 31 that started in 2017, is one of 42 in phase 3, and was the 121st registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, double-blind, saline placebo- and active-controlled, multicenter study to evaluate the analgesic efficacy and safety of HTX 011 administered via local administration into the surgical site in subjects undergoing unilateral open inguinal herniorrhaphy.

03

Conditions studied

  • Postoperative Pain

Keywords

  • inguinal hernia
  • hernia
  • hernia surgery
  • postoperative pain
  • herniorrhaphy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is scheduled to undergo a unilateral open inguinal herniorrhaphy with mesh under general anesthesia.
  • Has an Physical Status of I, II, or III.
  • Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable .

Exclusion criteria

Exclusion Criteria:

  • Had any prior inguinal hernia repair.
  • Has a planned concurrent surgical procedure.
  • Has other pre existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.
  • Has a or a known or suspected history of or idiosyncratic reaction to required study medications.
  • Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.
  • Has taken NSAIDs within 10 days prior to the scheduled surgery.
  • Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting).
  • Has been administered bupivacaine within 5 days prior to the scheduled surgery.
  • Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.
  • Has been administered systemic within 5 half-lives or 10 days prior to administration of study drug.
  • Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
  • Has a known history of , (HIV), or active .
  • Has uncontrolled anxiety, psychiatric, or neurological disorder that, in the opinion of the Investigator, might interfere with study assessments.
  • Had a in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  • Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention deficit/hyperactivity disorder) may be eligible for participation in the study. Subjects taking medical marijuana are not allowed to participate in the study.
  • Received an product or device in a clinical trial within 30 days or within 5 elimination half lives.
  • Has undergone 3 or more surgeries within 12 months.
  • Has a (BMI) >39 kg/m2.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
418 participants (actual)

Study arms

  • Experimental
    Treatment Group 1: HTX-011

    HTX 011 (bupivacaine/meloxicam)

    Drug: HTX-011 · Device: Luer-lock applicator · Device: Vial access device

  • Active comparator
    Treatment Group 2: Bupivacaine HCI

    Bupivacaine HCl

    Drug: Bupivacaine HCl

  • Placebo comparator
    Treatment Group 3: Saline Placebo

    Saline placebo

    Drug: Saline placebo · Device: Luer-lock applicator

Interventions

  • DrugHTX-011

    Drug pages: Bupivacaine · Meloxicam

    HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation

  • Bupivacaine HCl without epinephrine, 75 mg by injection

  • DrugSaline placebo

    Saline placebo by instillation

  • DeviceLuer-lock applicator

    Applicator for instillation

  • DeviceVial access device

    Device for withdrawal of drug product

06

What researchers measure

Primary outcomes

  1. Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With Saline Placebo.

    Pain intensity is assessed using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-72 is 0-720. The prescribed activity for NRS-A is sitting up from a resting position.

    Time frame: 72 hours

Secondary outcomes

  1. Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With Bupivacaine HCl.

    Pain intensity is assessed using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-72 is 0-720. The prescribed activity for NRS-A is sitting up from a resting position.

    Time frame: 72 hours

  2. Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Saline Placebo.

    Time frame: 72 hours

  3. Percetange of Subjects Who Are Opioid-free for HTX-011 Compared With Bupivacaine HCl.

    Time frame: 72 hours

  4. Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Bupivacaine HCl.

    Time frame: 72 hours

07

Results

Posted Oct 27, 2021

Participant flow

Participant flow — Overall Study
MilestoneTreatment Group 1: HTX-011Treatment Group 2: Bupivacaine HCITreatment Group 3: Saline Placebo
Started16417282
Completed15917081
Not completed521
Withdrew: Lost to follow-up100
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject321

Outcome measures

PrimaryMean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With Saline Placebo.

Pain intensity is assessed using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-72 is 0-720. The prescribed activity for NRS-A is sitting up from a resting position.

Time frame:
72 hours
Reported as:
Mean · pain intensity score*hr
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With Saline Placebo.
pain intensity score*hrTreatment Group 1: HTX-011Treatment Group 3: Saline Placebo
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With Saline Placebo.269.39 ± 173.719350.82 ± 171.224
Statistical analysis
  • Treatment Group 1: HTX-011 vs Treatment Group 3: Saline Placebo · ANOVA · p = = 0.0004 · Least squares mean difference (lsmd): -81.43 · 95% CI -125.83 to -37.02
SecondaryMean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With Bupivacaine HCl.

Pain intensity is assessed using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-72 is 0-720. The prescribed activity for NRS-A is sitting up from a resting position.

Time frame:
72 hours
Reported as:
Mean · pain intensity score*hr
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With Bupivacaine HCl.
pain intensity score*hrTreatment Group 1: HTX-011Treatment Group 2: Bupivacaine HCI
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With Bupivacaine HCl.269.39 ± 173.719341.88 ± 158.303
Statistical analysis
  • Treatment Group 1: HTX-011 vs Treatment Group 2: Bupivacaine HCI · ANOVA · p = < 0.0001 · Least squares mean difference (lsmd): -72.49 · 95% CI -108.32 to -36.65
SecondaryMean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Saline Placebo.
Time frame:
72 hours
Reported as:
Mean · IV milligram morphine equivalent (MME)
Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Saline Placebo.
IV milligram morphine equivalent (MME)Treatment Group 1: HTX-011Treatment Group 3: Saline Placebo
Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Saline Placebo.10.85 ± 17.06217.53 ± 18.908
Statistical analysis
  • Treatment Group 1: HTX-011 vs Treatment Group 3: Saline Placebo · Wilcoxon (Mann-Whitney) · p = = 0.0001
SecondaryPercetange of Subjects Who Are Opioid-free for HTX-011 Compared With Bupivacaine HCl.
Time frame:
72 hours
Reported as:
Count of participants · Participants
Percetange of Subjects Who Are Opioid-free for HTX-011 Compared With Bupivacaine HCl.
ParticipantsTreatment Group 1: HTX-011Treatment Group 2: Bupivacaine HCI
Percetange of Subjects Who Are Opioid-free for HTX-011 Compared With Bupivacaine HCl.8469
Statistical analysis
  • Treatment Group 1: HTX-011 vs Treatment Group 2: Bupivacaine HCI · Fisher Exact · p = = 0.0486 · Risk difference (rd): 0.111 · 95% CI 0.003 to 0.218
SecondaryMean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Bupivacaine HCl.
Time frame:
72 hours
Reported as:
Mean · IV milligram morphine equivalent (MME)
Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Bupivacaine HCl.
IV milligram morphine equivalent (MME)Treatment Group 1: HTX-011Treatment Group 2: Bupivacaine HCI
Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) for HTX 011 Compared With Bupivacaine HCl.10.85 ± 17.06214.51 ± 18.185
Statistical analysis
  • Treatment Group 1: HTX-011 vs Treatment Group 2: Bupivacaine HCI · Wilcoxon (Mann-Whitney) · p = = 0.024

Adverse events

Collected over 28 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Group 1: HTX-0110/163 (0%)2/163 (1.2%)84/163 (51.5%)
Treatment Group 2: Bupivacaine HCI0/173 (0%)1/173 (0.6%)104/173 (60.1%)
Treatment Group 3: Saline Placebo0/82 (0%)1/82 (1.2%)49/82 (59.8%)
Most frequent serious events
Most frequent serious events
EventTreatment Group 1: HTX-011Treatment Group 2: Bupivacaine HCITreatment Group 3: Saline Placebo
Cellulitis of male external genital organInfections and infestations0/1630/1731/82
Postoperative wound infectionInfections and infestations0/1630/1731/82
Inguinal hernia, obstructiveGastrointestinal disorders0/1630/1731/82
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/1630/1730/82
Incision site haematomaInjury, poisoning and procedural complications1/1630/1730/82
PyrexiaGeneral disorders0/1631/1730/82
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTreatment Group 1: HTX-011Treatment Group 2: Bupivacaine HCITreatment Group 3: Saline Placebo
NauseaGastrointestinal disorders30/16337/17328/82
DizzinessNervous system disorders24/16342/17313/82
ConstipationGastrointestinal disorders28/16341/17315/82
HeadacheNervous system disorders21/16324/17310/82
DysgeusiaNervous system disorders15/16321/1733/82
TremorNervous system disorders7/16312/1738/82
BradycardiaCardiac disorders15/16316/1736/82
Skin odour abnormalSkin and subcutaneous tissue disorders13/1631/1731/82
Gamma-glutamyltransferase increaseInvestigations2/1635/1736/82
VomitingGastrointestinal disorders7/16312/1734/82

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment Group 1: HTX-011Treatment Group 2: Bupivacaine HCITreatment Group 3: Saline PlaceboTotal
<=18 years0000
Between 18 and 65 years14916177387
>=65 years1511531
Age, Continuous
Age, Continuous(years)Treatment Group 1: HTX-011Treatment Group 2: Bupivacaine HCITreatment Group 3: Saline PlaceboTotal
Mean48.9 ± 13.2949.4 ± 11.2648.0 ± 14.5948.9 ± 12.75
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Group 1: HTX-011Treatment Group 2: Bupivacaine HCITreatment Group 3: Saline PlaceboTotal
Female128323
Male15216479395
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Group 1: HTX-011Treatment Group 2: Bupivacaine HCITreatment Group 3: Saline PlaceboTotal
Hispanic or Latino435130124
Not Hispanic or Latino12112152294
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Group 1: HTX-011Treatment Group 2: Bupivacaine HCITreatment Group 3: Saline PlaceboTotal
American Indian or Alaska Native2002
Asian2215
Native Hawaiian or Other Pacific Islander4105
Black or African American1716336
White13915378370
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Treatment Group 1: HTX-011Treatment Group 2: Bupivacaine HCITreatment Group 3: Saline PlaceboTotal
Belgium4004
United States16017282414
08

Study locations

24 sites
  • Eliza Coffee Memorial Hospital
    Florence, Alabama 35630, United States
  • Shoals Medical Trials, Inc.
    Sheffield, Alabama 35660, United States
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Trovare Clinical Research, Inc.
    Bakersfield, California 93301, United States
  • Alliance Research Centers
    Laguna Hills, California 92653, United States
  • Lotus Clinical Research, LLC
    Pasadena, California 91105, United States
  • HD Research Corp
    Riverside, California 92503, United States
  • American Institute of Research
    Whittier, California 90603, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06511, United States
  • Cornerstone Research Institute, LLC
    Longwood, Florida 32750, United States
  • Park Place Surgery Center
    Maitland, Florida 32751, United States
  • University of Miami
    Miami, Florida 33136, United States
  • St. Louis Clinical Trials
    St Louis, Missouri 63141, United States
  • eStudySite
    Las Vegas, Nevada 89109, United States
  • Midwest Clinical Research
    Dayton, Ohio 45417, United States
  • Hermann Drive Surgical Hospital
    Houston, Texas 77004, United States
  • Westside Surgical Hospital
    Houston, Texas 77027, United States
  • Plano Surgical Hospital
    Plano, Texas 75093, United States
  • Endeavor Clinical Trials, P.A.
    San Antonio, Texas 78229, United States
  • EPIC Medical Research, LLC
    Murray, Utah 84123, United States
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
  • Jessa Ziekenhuis
    Hasselt, Limburg 3500, Belgium
  • Ziekenhuis Oost Limburg
    Genk, 3600, Belgium
09

References and documents

Publications

  • Minkowitz H, Soto R, Fanikos J, Hammer GB, Mehta N, Hu J, Redan J. Opioid-Free Recovery After Hernia Repair with HTX-011 as the Foundation of a Non-Opioid, Multimodal Analgesia Regimen in a Real-World Setting: A Randomized, Open-Label Study. Pain Ther. 2021 Dec;10(2):1295-1308. doi: 10.1007/s40122-021-00289-2. Epub 2021 Jul 27. PubMed 34318438 ↗
  • Yip T, Hu J, Hawn PS, Yamamoto A, Oderda G. HTX-011 effectively reduces postoperative pain intensity and opioid use in the elderly. Pain Manag. 2022 Jan;12(1):45-57. doi: 10.2217/pmt-2021-0043. Epub 2021 Jul 21. PubMed 34284613 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Dec 2017, 4 months.

Results were first posted in Oct 2021, 3 years 10 months after primary completion. A results delay was requested in Jun 2018.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 4 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2017
First posted
Aug 2, 2017
StartActual
Jul 31, 2017
Primary completionActual
Dec 22, 2017
CompletionActual
Jan 16, 2018
Results delay requested
Jun 8, 2018
Results first posted
Oct 27, 2021
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03237481
Lead sponsor
Heron Therapeutics
Responsible party
Sponsor
First posted
Aug 2, 2017
Start date
Jul 31, 2017
Primary completion
Dec 22, 2017
Completion
Jan 16, 2018
Results posted
Oct 27, 2021
Last update
Mar 2, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Meloxicam

Start the discussion